First Distribution Agreement Executed with Sonic Healthcare
5.7.2023 03:35:00 CEST | Business Wire | Press Release
Microba Life Sciences Limited (ASX: MAP) (“Microba”) is pleased to announce that it has executed a commercial agreement with Sonic Healthcare Limited (ASX: SHL) through a wholly owned subsidiary Douglass Hanly Moir Pathology Pty Ltd, to distribute Microba’s advanced infectious disease test MetaPanel™ in Australia (Distribution Agreement).
The announcement of the MetaPanel™ Distribution Agreement marks the first commercial agreement between Microba and Sonic Healthcare following the announcement to the ASX of the $17.8m strategic investment by Sonic Healthcare into Microba on 29 November 2022. At the time of the investment, Sonic and Microba agreed initial terms for a strategic partnership to distribute Microba’s microbiome testing technology into Sonic Healthcare’s major markets. The execution of this Distribution Agreement now completes the first of those commercial distribution arrangements, providing exclusive distribution rights to deliver the MetaPanel™ test Australia-wide through the Sonic Healthcare Australia Pathology network.
Microba’s Chief Executive Officer, Dr Luke Reid said, “We are excited to be bringing Microba's testing products to clinicians and their patients throughout Australia via Sonic Healthcare's specialist national laboratory network. The MetaPanel™ technology was developed over many years and represents a world-first in pathology through comprehensive metagenomic testing for gastrointestinal infectious diseases. Sonic Healthcare is a leading provider of high-quality pathology services and will lead the commercialisation efforts to deliver the MetaPanel™ test nationally. Sonic Australia is the first region to distribute Microba’s technology, with plans to deliver our testing technology and products into additional markets across the globe through our partnership”.
About the MetaPanel Technology
MetaPanel™ is an advanced in-vitro diagnostic for testing of causal agents of gastrointestinal infectious disease. The test employs Microba’s metagenomics technology to diagnose infectious pathogens such as bacteria, fungi, parasites and DNA viruses together with assessment of virulence factors and antimicrobial resistance (AMR) genes to support precise treatment decisions. The test helps clinicians to avoid multiple, low-coverage, and sequential diagnostic tests that can impact treatment outcomes for vulnerable patients. The MetaPanel™ technology seeks to create a new standard of care for gastrointestinal infectious disease pathology. Microba has worked intimately with clinical microbiologists and infectious disease experts to design the target list and support clinical validation, including the Sonic Healthcare Douglass Hanley Moir team – one of the most highly respected and high-quality pathology service teams in Australia, and leading clinician Professor Paul Griffin, Director of Infectious Diseases at the Mater Hospital Brisbane.
About the gastrointestinal infectious disease pathology market
It is estimated that there are over 16m patients globally per annum1, including over 100k patients in Australia1, which are high risk and susceptible to gastrointestinal infection who receive routine testing for pathogens in a hospital setting. In addition, globally there is growing concern regarding AMR and the overuse or misuse of antibiotics. This is driving advocacy and demand for increased use of pathogen and AMR testing to guide treatment decisions and best practice antibiotic prescriptions. Current diagnostic testing methods include culturing technologies and nucleic acid amplification tests such as polymerase chain reaction (PCR). These current testing methods are limited in their ability to cover the full diversity of pathogens, subtypes and AMR genes, and are often subject to sequential testing which delays critical treatment decisions. Microba’s MetaPanel™ technology has the opportunity create a new standard through employing advanced metagenomics to deliver broad coverage of pathogens, AMR and virulence factor genes from a single test to guide targeted treatment.
About Sonic Healthcare
Sonic Healthcare is one of the world’s leading healthcare providers, with a reputation for excellence in laboratory medicine/pathology, radiology and primary care medical services, across operations in Australasia, Europe and North America. The group provides highly specialised pathology/clinical laboratory and radiology services to clinicians (GPs and specialists), hospitals, community health services, and their patients. Sonic is the world’s third-largest provider of pathology/clinical laboratory services (referred to in some markets as 'laboratory medicine').
Employing over 41,000 people globally, Sonic is the largest private pathology operator in Australia, Germany, Switzerland and the UK, the second-largest in Belgium and New Zealand and the third-largest in the USA.
About Microba Life Sciences Limited
Microba Life Sciences is a precision microbiome company driven to improve human health. With world-leading technology for measuring the human gut microbiome, Microba is driving the discovery and development of novel therapeutics for major chronic diseases and delivering gut microbiome testing services globally to researchers, clinicians, and consumers. Through partnerships with leading organisations, Microba is powering the discovery of new relationships between the microbiome, health and disease for the development of new health solutions.
1 Estimated based on the global number of immuno-compromised patients and other patients at high risk for gastrointestinal infection (>8.1m global and >68k Australian chemotherapy treated solid tumor cancer patients, and >1.1m global and >8k Australian haematological cancer patients DOI::https://doi.org/10.1016/S1470-2045(19)30163-9), (>3m global and 12k Australian dialysis patients DOI: 10.1038/s41581-022-00542-7), (>140k global and >1k Australian Organ Transplant patients per year https://www.transplant-observatory.org/), (>3.5m global and >25k long stay ICU patients – estimate based on data from https://ourworldindata.org/grapher/intensive-care-beds-per-100000 )
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230704692043/en/
Contact information
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Enry’s Island Unveils “Enry’s Island Adventures”: Venture Capital Becomes a Videogame and Launches the “Strap” Movement on Kickstarter3.4.2026 09:47:00 CEST | Press Release
Enry’s Island SpA (WBAG: EIOS), the world’s first publicly traded Venture Builder, today announced the upcoming Kickstarter launch of Enry’s Island Adventures (EIA), developed by its New York-based portfolio company, Enry’s Island Adventures LLC. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402548535/en/ The game is designed to make venture capital accessible to new generations, transforming startup creation into an engaging and social gaming experience. After three years of R&D, EIA introduces a "bleisure" model (business + leisure): players learn to launch and manage startups through gameplay that includes real business KPIs, a customizable and evolving personal island, synchronous and asynchronous multiplayer modes, social events, and community-driven seasonal missions. The “VC revolution”: teaching and democratizing through play "I agree with Elon Musk that the best way to teach is through a video game, and this is
SES Announces Results of the Annual General Meeting2.4.2026 16:49:00 CEST | Press Release
SES (the “Company”) held the Annual General Meeting (“AGM”) of Shareholders today in Betzdorf, Luxembourg. Following the recommendations made by the Board of Directors of SES, the shareholders have voted in favor of all resolutions, including the Company’s 2025 annual accounts and the proposed annual dividend of EUR 0.50 per A-share (EUR 0.20 per B-share). The total dividend amount comprises the interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share), which has already been paid to shareholders on October 16, 2025. The final dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) will be paid to shareholders on April 16, 2026. “I would like to sincerely thank our shareholders for their active engagement, visionary support and continued confidence in SES’ strategy,” said Adel Al-Saleh, CEO of SES. “The outcomes of today’s AGM underscore our shared commitment to a bold multi-orbit approach, with Medium Earth Orbit as the strategic backbone of a dynamically evolving global interco
Forrester: Three Years Into GenAI, Enterprises Are Still Chasing Its True Transformative Value2.4.2026 16:00:00 CEST | Press Release
According to Forrester’s (Nasdaq: FORR) latest report, Accelerate Your AI Voyage, most enterprises are struggling to turn growing AI adoption and investment into measurable business impact. One of the key factors holding businesses back is low artificial intelligence quotient (AIQ) — Forrester’s measure of AI aptitude — with many employees lacking a clear understanding of how to use AI. Other barriers include an overemphasis on productivity-focused use cases, difficulty measuring impact, and siloed adoption within individual functions. While these challenges can leave firms frozen in doubt or indecision, the wait-and-see approach to AI adoption is no longer viable. To unlock AI’s full potential, organizations need to focus on four key areas: Define the business outcomes and success metrics for what they want AI to achieve; identify specific use cases for AI deployment aligned to those business outcomes; establish a structured runway to plan, test, and strategically time the deployment
Andersen Consulting Adds Multiplica2.4.2026 15:30:00 CEST | Press Release
Andersen Consulting enters into a Collaboration Agreement with Multiplica, a digital consulting firm that helps organizations design, build, and scale impactful digital experiences. Founded in Spain with a presence in Latin America and the U.S., Multiplica focuses on user research and discovery, customer experience research, digital strategy, data modeling and analysis, report automation and data visualization, conversion rate optimization, product design, and user experience design. The firm helps organizations accelerate digital transformation by building digital capabilities, teams, and assets that advance expertise across digital products, consulting, and talent development. Multiplica enables clients to forecast emerging trends in digital experience and transform their businesses through enhanced digital channels and customer engagement. “Collaborating with Andersen Consulting represents an exciting opportunity to extend our reach and impact,” said David Boronat, CEO of Multiplica
The LYCRA Company Announces Strategic Partnership on Renewable LYCRA ® Fiber2.4.2026 15:00:00 CEST | Press Release
The LYCRA Company, a global leader in innovative and sustainable fiber solutions for the apparel and personal care industries, today announced the signing of a strategic partnership agreement with Texhong International Group Limited (“Texhong”), one of the world’s largest suppliers of core-spun cotton textiles. Under the agreement, Texhong will exclusively partner with The LYCRA Company to bring Renewable LYCRA® fiber made with 30 percent plant-based content* to China’s core-spun yarn sector. This collaboration aims to accelerate the adoption of bio-derived spandex across the global apparel and textile industry. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260402505834/en/ The LYCRA Company announced a strategic partnership with Texhong International Group for renewable LYCRA® fiber. Pictured at the signing ceremony held in Shanghai (left to right): Jason Wang, Vice President, Asia, The LYCRA Company, and Zhou Xia, Chief O
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom